

DRUG QUANTITY MANAGEMENT POLICY – PER RX

POLICY: Multiple Sclerosis – Mayzent Drug Quantity Management Policy – Per Rx

- Mayzent® (siponimod tablets – Novartis)

REVIEW DATE: 04/20/2022

OVERVIEW

Mayzent is indicated for the treatment of relapsing forms of **multiple sclerosis**, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.¹

Dosing

For patients with cytochrome P450 (CYP)2C9 genotypes *1/*1, *1/*2, or *2/*2, the maintenance dose is 2 mg daily following a 5-day titration.¹ For patients with CYP2C9 genotypes *1/*3 or *2/*3, the maintenance dose is 1 mg daily following a 4-day dose titration. Dose titration for all patients is accomplished using the 0.25 mg tablets. After the initial titration is complete, if Mayzent treatment is interrupted for ≥ 4 consecutive days, treatment is re-started with Day 1 of the titration regimen.

Availability

Mayzent is available as tablets in the following strengths: 0.25 mg, 1 mg, and 2 mg.¹ The 0.25 mg tablets are available in bottles of 28 tablets; the 1 mg and 2 mg tablets are available in bottle of 30 tablets. In addition, two blister packs are available: 7-tablet starter pack for a 1 mg daily maintenance dose (contains seven 0.25-mg) and a 12-tablet starter pack for the 2 mg daily maintenance dose (contains 12 x 0.25-mg tablets). The 12-tablet starter pack should be used for all patients who will be titrated to the 2-mg maintenance dose. Unopened containers should be stored in the refrigerator, and once dispensed may be stored at room temperature for up to 3 months. The blister packs should be stored in their original blister wallet container.

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Mayzent. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Maximum Quantity per Rx
Mayzent® (siponimod tablets)	0.25 mg tablets (bottle of 28 tablets)	30
	0.25 mg tablets (7-tablet Starter Pack)	7
	0.25 mg tablets (12-tablet Starter Pack)	12
	1 mg tablets (bottle of 30 tablets)	30
	2 mg tablets (bottle of 30 tablets)	30

04/20/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

CRITERIA

Mayzent 0.25 mg

No overrides recommended.

Mayzent 2 mg

No overrides recommended.

REFERENCES

1. Mayzent® tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; March 2022.